000303036 001__ 303036
000303036 005__ 20250723114148.0
000303036 0247_ $$2doi$$a10.1093/neuonc/noaf173
000303036 0247_ $$2pmid$$apmid:40692474
000303036 0247_ $$2ISSN$$a1522-8517
000303036 0247_ $$2ISSN$$a1523-5866
000303036 037__ $$aDKFZ-2025-01483
000303036 041__ $$aEnglish
000303036 082__ $$a610
000303036 1001_ $$avan den Bent, Martin J$$b0
000303036 245__ $$aThe Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspective.
000303036 260__ $$aOxford$$bOxford Univ. Press$$c2025
000303036 3367_ $$2DRIVER$$aarticle
000303036 3367_ $$2DataCite$$aOutput Types/Journal article
000303036 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1753189179_32231
000303036 3367_ $$2BibTeX$$aARTICLE
000303036 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303036 3367_ $$00$$2EndNote$$aJournal Article
000303036 500__ $$aepub
000303036 520__ $$aThe RANO criteria for response to treatment in glioma make a distinction between enhancing and unenhancing tumors, which reflects assessment of a different biological process underlying the MRI findings in enhancing and non-enhancing tumors. The recent regulatory approval of tovorafenib has also considered the patients with minor responses (25% - 50% decrease) based on the 2D measurement on T2/FLAIR MR imaging, while incorporating other measures of patient benefit. The INDIGO placebo controlled trial led to the regulatory approval of vorasidenib based on the increase in PFS in the active treatment arm, as measured by blinded independent radiology review using the 2D RANO criteria. With that, more insight in the regulatory requirements for approval in low grade tumors has been obtained, but other issues in assessing outcome in studies on low grade enhancing tumors remain. These include the added value of volumetric assessment instead of 2D assessments, and assessment of tumor growth rate as an early marker of outcome. This manuscript gives an overview of the current perspective on and challenges of assessing outcome in trials on unenhancing glioma, with both regulatory and clinical perspectives.
000303036 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000303036 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303036 650_7 $$2Other$$aMinor Response
000303036 650_7 $$2Other$$aRANO
000303036 650_7 $$2Other$$aTumor Growth rate
000303036 650_7 $$2Other$$aunenhancing tumors
000303036 650_7 $$2Other$$avolumetric (3D) assessment
000303036 7001_ $$00000-0002-8656-7483$$aCloughesy, Timothy F$$b1
000303036 7001_ $$00000-0002-2764-6640$$aEllingson, Benjamin M$$b2
000303036 7001_ $$aAllen, Joshua E$$b3
000303036 7001_ $$00000-0003-1076-8921$$aBlackman, Samuel C$$b4
000303036 7001_ $$aKieran, Mark W$$b5
000303036 7001_ $$00009-0004-1756-423X$$aTonn, Joerg C$$b6
000303036 7001_ $$00000-0002-1254-5310$$aKarschnia, Philipp$$b7
000303036 7001_ $$00000-0002-2690-5022$$aWijnenga, Maarten$$b8
000303036 7001_ $$00000-0002-1652-9844$$aPallud, Johan$$b9
000303036 7001_ $$00000-0001-7003-3017$$aYoung, Robert J$$b10
000303036 7001_ $$00000-0001-7661-797X$$aHuang, Raymond Y$$b11
000303036 7001_ $$00000-0002-4347-8149$$aMellinghoff, Ingo K$$b12
000303036 7001_ $$00000-0003-1454-6461$$ade Groot, John$$b13
000303036 7001_ $$00000-0003-4649-327X$$avan der Hoorn, Anouk$$b14
000303036 7001_ $$00000-0001-6109-7692$$aYoussef, Gilbert$$b15
000303036 7001_ $$00000-0003-4699-260X$$aHervey-Jumper, Shawn L$$b16
000303036 7001_ $$aVogelbaum, Michael A$$b17
000303036 7001_ $$aChang, Susan M$$b18
000303036 7001_ $$aWen, Patrick Y$$b19
000303036 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noaf173$$gp. noaf173$$pnn$$tNeuro-Oncology$$vnn$$x1522-8517$$y2025
000303036 909CO $$ooai:inrepo02.dkfz.de:303036$$pVDB
000303036 9101_ $$0I:(DE-588b)2036810-0$$60009-0004-1756-423X$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000303036 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000303036 9141_ $$y2025
000303036 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000303036 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000303036 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000303036 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000303036 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000303036 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000303036 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000303036 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000303036 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000303036 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000303036 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000303036 980__ $$ajournal
000303036 980__ $$aVDB
000303036 980__ $$aI:(DE-He78)MU01-20160331
000303036 980__ $$aUNRESTRICTED